Troy A. Ignelzi - Apr 19, 2022 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role
Chief Financial Officer
Signature
/s/ Troy Ignelzi
Stock symbol
KRTX
Transactions as of
Apr 19, 2022
Transactions value $
-$517,941
Form type
4
Date filed
4/21/2022, 07:04 PM
Previous filing
Feb 17, 2022
Next filing
Aug 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $32.2K +3.5K +14.02% $9.20* 28.5K Apr 19, 2022 Direct
transaction KRTX Common Stock Sale -$458K -3.5K -12.29% $130.81 25K Apr 19, 2022 Direct F1, F2
transaction KRTX Common Stock Options Exercise $6.48K +704 +2.82% $9.20* 25.7K Apr 20, 2022 Direct
transaction KRTX Common Stock Sale -$93.8K -704 -2.74% $133.20 25K Apr 20, 2022 Direct F1
transaction KRTX Common Stock Options Exercise $368 +40 +0.16% $9.20* 25K Apr 21, 2022 Direct
transaction KRTX Common Stock Sale -$5.38K -40 -0.16% $134.46 25K Apr 21, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -3.5K -2.2% $0.00 155K Apr 19, 2022 Common Stock 3.5K $9.20 Direct F3
transaction KRTX Option (right to buy) Options Exercise $0 -704 -0.45% $0.00 155K Apr 20, 2022 Common Stock 704 $9.20 Direct F3
transaction KRTX Option (right to buy) Options Exercise $0 -40 -0.03% $0.00 155K Apr 21, 2022 Common Stock 40 $9.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 1, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $130.78 to $130.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2019, with additional vesting as to 12.5% of the shares underlying the option award on each six month period thereafter.